Company Intelligence Profile
Premas Life Sciences Private Limited
Premas Life Sciences Pvt Ltd (founded/incorporated 2011, per official site marketing material sometimes traces roots to 2005) is a Delhi-based life-sciences distribution and technology-partner company serving India's research and clinical-diagnostics community.
CIN: U51909DL2011PTC217592Active (compliant); Registered on 15 April 2011RoC-Delhi (Falconebiz specifies "RoC-Delhi I")Confidence: medium-high — identity
AI OverviewGenerated from public records
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
Company Identity
Confirmed| Registered name | Premas Life Sciences Private Limited |
|---|---|
| CIN | U51909DL2011PTC217592 |
| PAN | AAGCP0079F (Source: Tofler; single-source, not cross-confirmed elsewhere — treat as partial) |
| Status | Active (compliant); Registered on 15 April 2011 |
| Listing | Unlisted (private limited company) |
| Incorporated | 15 April 2011 (Source: Tofler, TheCompanyCheck, Falconebiz — all agree) |
| ROC | RoC-Delhi (Falconebiz specifies "RoC-Delhi I") |
| Sector (NIC) | MCA activity code: "Other wholesale n.e.c." (Tofler, Falconebiz). Falconebiz further classifies as Healthcare/Medical Equipment Retail & Distribution, Wholesale Trading (Group G1) and Professional/Scientific/Technical Activities (Group M9). DPIIT-recognised Startup per Falconebiz. |
| Registered address | Second Floor, E-49/5, Okhla Industrial Estate, Phase-II, New Delhi, Delhi - 110020 (Source: Tofler, TheCompanyCheck, Falconebiz — all agree) |
| Authorized capital | Rs 30,00,00,000 (Rs 30 Cr) — confirmed by Tofler, TheCompanyCheck, Falconebiz |
| Paid-up capital | Rs 28,73,32,740 (~Rs 28.73 Cr) — confirmed by Tofler, TheCompanyCheck, Falconebiz (three-source agreement). Note: one search-engine snippet attributed to a blocked/cached ZaubaCorp-type listing showed a conflicting figure (~Rs 1.5 Cr paid-up); this is disregarded as it comes from a source excluded per sourcing rules and conflicts with 3 independent confirmations. |
Business Overview
Confirmed- Premas Life Sciences Pvt Ltd (founded/incorporated 2011, per official site marketing material sometimes traces roots to 2005) is a Delhi-based life-sciences distribution and technology-partner company serving India's research and clinical-diagnostics community
- It distributes advanced instruments and consumables across Genomics (Illumina sequencing platforms — MiSeq i100, NovaSeq series
- library prep kits
- Covaris), Proteomics (Olink Signature biomarker discovery), and Cell Analysis (Cytek Aurora spectral flow cytometry, SphereBio Cyto-Mine single-cell platforms), serving human health, agriculture, biopharma, environment, forensics and energy applications
- Represents 15+ global technology brands (including long-standing ~12+ year partnership with Illumina per CRISIL rationale) with 700+ installations across India, 85-101 employees including 20+ PhD-qualified staff, and 260+ research collaborations
- (Sources: company website premaslifesciences.com, CRISIL rating rationale, TheCompanyCheck)
Directors
Confirmed| Name | DIN | Role | Appointed |
|---|---|---|---|
| Praveen Kumar Gupta | 03468769 | Managing Director, DIN 03468769, appointed 15 Apr 2011 co-founder/MD & CEO | 15 Apr 2011 |
| Debjit Patra | 00008935 | Director, DIN 00008935, appointed 20 Mar 2016 | 20 Mar 2016 |
| Avijit Das | 00398852 | Director, DIN 00398852, appointed 15 Apr 2011 co-founder. Additional TheCompanyCheck/Falconebiz only, DIN not obtained: Ashok Jain; CFO, DIN 08146711 per Falconebiz, appointed 9 Sep 2022. | 15 Apr 2011 |
Financials
Partial / conflicting- Standalone figures (entity is unlisted, files standalone accounts)
- Revenue trend (Source: TheCompanyCheck / Tracxn-derived web snippets, financial-year ending 31 March): FY2022 ~Rs 328.01 Cr (per CRISIL rationale, boosted by COVID-19 testing-kit sales)
- FY2023 ~Rs 256.3 Cr (CRISIL rationale — reflects normalization post-COVID, ~12% underlying growth ex-pandemic sales)
- FY2024 per search-snippet described as +20.37% net-sales growth and +23.63% total-assets growth YoY (source snippet did not name absolute figure, treat as partial)
- FY2025 (year ended 31 Mar 2025) revenue ~Rs 309.66-310 Cr, down ~2% YoY (TheCompanyCheck, corroborating web-search snippet)
- Net worth: ~Rs 160 Cr as of FY2023 (CRISIL rationale)
- Gearing: 0.05x (near debt-free on a net basis) as of FY2023 (CRISIL)
- Interest coverage 34.8x, net cash accrual-to-debt 3.9x (FY2023, CRISIL)
- EBITDA/PAT absolute figures: not obtained (locked behind premium paywalls on TheCompanyCheck/Falconebiz)
- 3-year revenue CAGR ~43% per CRISIL (to FY2023)
- more recent-period CAGR figures from search snippets show revenue CAGR -2% and EBITDA CAGR +2% (1-year, to FY2025) — treat as partial/unverified single-source
- Total employees ~88-101 (EPFO/company site, FY2024-25)
Funding
Confirmed- No institutional/VC/PE funding rounds identified for Premas Life Sciences Private Limited — company appears to be entirely promoter/founder funded and bank-debt financed (per CRISIL: near-zero net gearing, healthy net worth from accruals)
- Caution: a similarly-named but distinct entity, "Premas Biotech Private Limited" (a biopharma/vaccine-tech company, different CIN), has raised ~$2.68M in VC funding per Crunchbase/PitchBook/Tracxn — this funding must NOT be attributed to Premas Life Sciences (entity-confusion trap flagged and avoided)
Charges/Loans
Partial / conflicting- Total open charges: ~Rs 132 Cr (Falconebiz)
- Key charge-holders: HDFC Bank Limited — Rs 80 Cr, registered 29 Nov 2021, Open
- Others — Rs 27 Cr, registered 22 Dec 2021, Open
- Citibank N.A. — Rs 25 Cr, registered 14 Mar 2019, Open
- Satisfied charges: Rs 0 reported
- (Single-source: Falconebiz
- not independently cross-confirmed, treat as partial.)
Credit Ratings
Confirmed- CRISIL Ratings (Source: crisilratings.com official rationale, dated 21 July 2023): Long-term "CRISIL BBB+/Stable" (reaffirmed)
- Short-term "CRISIL A2" (reaffirmed)
- Enhanced bank facilities from Rs 43 Cr to Rs 78 Cr at the time
- Facility breakdown: Cash Credit ~Rs 59 Cr (across three lenders), Bank Guarantees Rs 8 Cr, Letter of Credit Rs 10 Cr, proposed fund-based limits Rs 1 Cr. No ICRA or CARE rating found for this entity
Competitors
Partial / conflicting- Distribution/genomics-instrumentation peer set in India (rough scale tags, all approximate/relative): 1) Agilent Technologies India — global instrumentation major, much larger scale
- 2) Thermo Fisher Scientific India — global major, much larger
- 3) Roche Diagnostics India — large diversified diagnostics/instrumentation player
- 4) Datar Cancer Genetics — specialized genomics/diagnostics player, comparable-to-smaller scale
- 5) Miric Biotech — smaller specialized life-science distributor, comparable scale
- 6) Global platform vendors referenced as adjacent/partner-competitors in market analyses: Oxford Nanopore, PacBio, QuantuMDx (these are instrument OEMs Premas may also distribute-adjacent products for, named as "competitors" in aggregator databases — treat with caution)
- (Source: Tracxn/CBInsights-derived web search snippets — partial/unverified, single-source aggregator data.)
Frequently Asked Questions
What does Premas Life Sciences Private Limited do?
Premas Life Sciences Pvt Ltd (founded/incorporated 2011, per official site marketing material sometimes traces roots to 2005) is a Delhi-based life-sciences distribution and technology-partner company serving India's research and clinical-diagnostics community.
What is the CIN of Premas Life Sciences Private Limited?
The Corporate Identification Number (CIN) of Premas Life Sciences Private Limited is U51909DL2011PTC217592.
Where is Premas Life Sciences Private Limited registered?
Premas Life Sciences Private Limited is registered with RoC-Delhi (Falconebiz specifies "RoC-Delhi I"). Registered address: Second Floor, E-49/5, Okhla Industrial Estate, Phase-II, New Delhi, Delhi - 110020 (Source: Tofler, TheCompanyCheck, Falconebiz — all agree)
When was Premas Life Sciences Private Limited incorporated?
Premas Life Sciences Private Limited was incorporated on 15 April 2011 (Source: Tofler, TheCompanyCheck, Falconebiz — all agree).
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.